AP NEWS

Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis to 2023 - ResearchAndMarkets.com

August 23, 2018

DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023” report has been added to ResearchAndMarkets.com’s offering.

The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells.

The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry’s growth.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates

5.1 ADCETRIS

5.2 Kadcyla

5.3 Mylotarg

5.4 Besponsa

6. Antibody Drug Conjugates Pipeline Analysis

6.1 By Companies

6.1.1 By Clinical Phase

6.1.2 By Indication

6.1.3 By Drug

6.1.4 By Type of Linker

6.1.5 By Technology

6.2 By Research Organizations

6.2.1 By Phase

6.2.2 By Indication

6.2.3 By Drug

6.2.4 By Type of Linker

6.2.5 By Technology

7. Drivers and Challenges

7.1 Drivers

7.1.1 Rising Global Cancer Epidemics

7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC

7.1.3 Efforts towards Patent Protection to Drive ADC Market

7.1.4 Increasing Demand for Antibody Drug Conjugates

7.2 Challenges

7.2.1 Production Hurdles and Cost

7.2.2 Inadequacy of Experienced Manufacturers

7.2.3 Regulatory Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline

8.1 By Companies

8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex

8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.

8.1.3 Indatuximab Ravtansine/BT-062 - Biotest AG

8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals

8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.

8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.

8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.

8.2 By Research Organizations

8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands

8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital

9. Trends and Developments

9.1 ADC at the Forefront of Treating Hematological Malignancies

9.2 ADCs Proving Advantageous for Breast Cancer Patients

10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

11. Competitive Assessment

11.1 Seattle Genetics, Inc.

11.2 F. Hoffman-La Roche Ltd.

11.3 Pfizer Inc.

11.4 ImmunoGen, Inc.

11.5 Bayer AG

11.6 Takeda Pharmaceutical Company Limited

11.7 Immunomedics, Inc.

11.8 Oxford BioTherapeutics

11.9 Concortis Biotherapeutics

11.10 NBE-Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/cfb2x2/global_antibody?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005262/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 04:38 AM/DISC: 08/23/2018 04:38 AM

http://www.businesswire.com/news/home/20180823005262/en

AP RADIO
Update hourly